Welcome to our dedicated page for bli news (Ticker: bli), a resource for investors and traders seeking the latest updates and insights on bli stock.
Berkeley Lights, Inc. operates as a leading biotechnology company dedicated to providing cutting-edge technology solutions for single-cell manipulation. The company's innovative platform facilitates advancements in biopharma, diagnostics, and life science research. Berkeley Lights leverages its proprietary OptoSelect™ technology to enable precise control over biological processes at the single-cell level.
Headquartered in the United States, Berkeley Lights serves a global customer base, including leading pharmaceutical companies, research institutions, and diagnostics firms. The company's technology empowers researchers to discover new drugs, create better diagnostics, and develop innovative therapies.
One of the notable recent achievements of Berkeley Lights is the expansion of its platform capabilities, enhancing the efficiency and accuracy of single-cell analysis. The company has also formed strategic partnerships with key industry players to drive further innovation and market reach.
Financially, Berkeley Lights continues to show robust performance, with steady revenue growth and strategic investments in research and development. The company is committed to maintaining a strong financial position to support its mission of advancing human health through groundbreaking biotechnological solutions.
Current projects include the development of advanced cell therapy applications and expanding the use of their technology in various research and clinical settings. These projects highlight Berkeley Lights' commitment to pushing the boundaries of what's possible in biotechnology.
Overall, Berkeley Lights, Inc. stands at the forefront of biotechnology, offering unparalleled solutions for single-cell research and manipulation. The company's dedication to innovation and quality makes it a significant player in the life sciences sector.
Berkeley Lights (Nasdaq: BLI) announced a breakthrough in cancer treatment through a collaboration with the Jaime Leandro Foundation. They discovered a patient-derived T cell receptor sequence that effectively targets a cancer neoantigen, leading to complete remission in a patient with advanced pancreatic cancer. Utilizing the Berkeley Lights Beacon® system, the team achieved rapid functional validation of T cells, which enhances the process of developing personalized cancer vaccines. This advancement signifies a major step forward in immunotherapy and personalized medicine.
Berkeley Lights, a leader in digital cell biology, will participate in the 14th Annual Bioprocessing Summit from August 15-18, 2022 in Boston. As a premier sponsor, the company will showcase its Beacon® optofluidic platform at booth #413, allowing attendees to experience hands-on demonstrations. Aurora Fabry-Wood, Ph.D. will present on identifying top producers in cell line development. The Opto® Cell Line Development workflow integrates high throughput cell sorting and productivity assays into a five-day automated process. For more info, visit the Berkeley Lights website.
Berkeley Lights, Inc. (Nasdaq: BLI) announced the appointment of Rolando Brawer, Ph.D., as executive vice president for Strategy & Corporate Development, effective immediately. Dr. Brawer, with over two decades of experience in corporate development, will enhance the company's growth strategy through mergers, acquisitions, and partnerships. CEO Siddhartha Kadia expressed confidence in Dr. Brawer's potential to drive results and shareholder value. Previously, Dr. Brawer held significant roles at Danaher Corporation and other life sciences firms, contributing to substantial annual licensing revenue growth.
Berkeley Lights (BLI) and Aanika BioSciences have successfully identified a commercially viable antimicrobial peptide (AMP) in their strategic partnership aimed at improving food safety. This milestone was achieved ahead of schedule, leveraging Berkeley Lights' high-throughput functional screening services to optimize AMPs that reduce contamination in fresh produce. The partnership enables Aanika to expedite market entry and potentially enhance the global food system's safety and sustainability. Berkeley Lights will also benefit from downstream economics through a royalty arrangement.
Berkeley Lights, Inc. (Nasdaq: BLI) has appointed Mehul Joshi as chief financial officer (CFO), effective immediately. Joshi brings extensive experience from ResMed, where he played a key role in driving transformational growth. CEO Siddhartha Kadia emphasized Joshi's strategic financial expertise as vital for advancing the company's goals. Berkeley Lights specializes in digital cell biology, focusing on the rapid development of biotherapeutics. The company aims to provide advanced solutions for single-cell analysis to establish industry standards.
Berkeley Lights, Inc. (Nasdaq: BLI) will announce its second quarter 2022 financial results on August 9, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access the live audio webcast on the company’s website, which will also be available for replay. As a digital cell biology leader, Berkeley Lights focuses on accelerating biotherapeutics development through advanced technology, including the proprietary Berkeley Lights Platform for characterizing single cells.
Berkeley Lights, Inc. (BLI) is set to participate in the 27th Annual European Society for Animal Cell Technology (ESCAT) from June 26-29, 2022, in Lisbon, Portugal. The company will showcase its Beacon Platform at booth #39, demonstrating advanced cell line engineering and development techniques. Highlighted will be a symposium session on June 26, featuring insights from Rennos Fragkoudis of the Edinburgh Genome Foundry and Peter O’Callaghan of Lonza. They will discuss innovations in high-throughput single-cell screening and their application in gene therapy and vaccine development.
Berkeley Lights, Inc. (Nasdaq: BLI) has partnered with Curia to enhance antibody-based drug discovery through the adoption of Berkeley's Beacon® Optofluidic system. This collaboration will leverage Curia's proprietary platforms for high-throughput, single-cell experiments, aiming to expedite the drug development timeline from months to weeks. Curia's integration of the Beacon system promises unique and diverse antibody sequences with comprehensive data analysis, supporting faster progression from discovery to clinical trials.
Berkeley Lights (BLI) reported a total revenue of $20.2 million for Q1 2022, reflecting an 8.5% year-over-year growth. The company achieved a gross profit of $13.8 million with a gross margin of 68%. Despite these positives, operating expenses increased to $35.1 million, leading to a net loss of $21.4 million compared to $15.4 million in the previous year. New CEO Siddhartha Kadia emphasized opportunities for profitable growth and innovations in technology.
Berkeley Lights (Nasdaq: BLI) announces participation in the 18th Annual PEGS Boston Conference, occurring from May 2-6, 2022. The company will present a new poster on a high-throughput workflow for TCR discovery and host two podium talks showcasing its Beacon® platform. Key presentations include:
- Poster P021: Focused on TCR discovery and live single T cell analysis.
- Podium Presentation on May 3: Discusses high-throughput visualization for therapeutic development.
- Podium Presentation on May 4: Outlines the OPBD 4.0 workflow for antibody discovery.
FAQ
What is the market cap of bli (bli)?
What does Berkeley Lights, Inc. do?
Who are the customers of Berkeley Lights?
What is OptoSelect™ technology?
Has Berkeley Lights achieved any recent milestones?
What are Berkeley Lights' current projects?
How is Berkeley Lights performing financially?
Where is Berkeley Lights headquartered?
What impact does Berkeley Lights have on the biotechnology sector?
What is the significance of their technology in biopharma?
Who are some of Berkeley Lights' strategic partners?
